The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN.
1 report, 1 independent
Updated Jun 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA granted accelerated approval for the drug TRUTAKNA for use in patients with IgAN.Sub-event
- CorMedix sought FDA approval for its REZZAYO submission on June 16, 2026.Sub-event
- Lexeo Therapeutics has sought the FDA accelerated approval pathway for its medical treatment.Sub-event
Review of C5 complement inhibitor for IgAN.1 source